Classifications: cerebral stimulant; anorexiant; Therapeutic: anorexiant
Pregnancy Category: X
Controlled Substance: Schedule III
50 mg tablets
Indirect acting sympathomimetic amine with amphetamine-like actions but with fewer side effects than amphetamine. Anorexiant
effect thought to be secondary to stimulation of hypothalamus to release stored catecholamines in the CNS.
Effective as an appetite suppressant.
Short-term adjunct in management of exogenous obesity.
Known hypersensitivity to sympathomimetic amines; angle-closure glaucoma; advanced arteriosclerosis, angina pectoris, severe
cardiovascular disease, moderate to severe hypertension; hyperthyroidism, agitated states; history of drug abuse; children
<12 y; lactation; pregnancy (category X).
Diabetes mellitus; older adults; psychosis.
Route & Dosage
Adult: PO 2550 mg 13 times/d
- Give as a single daily dose, preferably midmorning or midafternoon, according to patient's eating habits.
- Schedule daily dose no later than 6 h before patient retires to avoid insomnia.
- Store in tight, light-resistant containers at 15°30° C (59°86° F) unless otherwise directed.
Adverse Effects (≥1%)CNS:
Euphoria, irritability, hyperactivity, nervousness, restlessness, insomnia,
tremor, headache, light-headedness, dizziness, depression
following stimulant effects. CV: Palpitation,
tachycardia, elevated BP, irregular heartbeat. GI:
Xerostomia, nausea, vomiting, diarrhea or constipation
, abdominal cramps. Chronic Intoxication:
, irritability, hyperactivity, personality changes, psychosis, severe dermatoses.
InteractionsDrug: Acetazolamide, sodium bicarbonate
elimination; ammonium chloride, ascorbic acid
may antagonize the effects of both drugs; furazolidone
may increase BP effects of amphetamines
, and interaction may persist for several weeks after discontinuation of furazolidone; guanethidine
antagonizes antihypertensive effects; because mao inhibitors
can cause hypertensive crisis (fatalities reported); do not administer amphetamines
during or within 14 d of these drugs; phenothiazines
may inhibit mood-elevating effects of amphetamines
; tricyclic antidepressants
effects because they increase norepinephrine
release; beta agonists
adverse cardiovascular effects.
Readily absorbed from GI tract. Duration:
4 h. Metabolism:
Via CYP3A4. Elimination:
Assessment & Drug Effects
- Assess for signs of excessive CNS stimulation: insomnia, restlessness, tremor, palpitations. These may indicate need for
- Monitor vital signs; report elevated BP, tachycardia, and irregular heart rhythm.
- Monitor diabetics for loss of glycemic control.
Patient & Family Education
- Note: Anorexiant effects are temporary and tolerance may occur; long-term use is not indicated.
- Do not drive or engage in potentially hazardous activities until response to drug is known.
- Do not terminate high dosage therapy abruptly; GI distress, stomach cramps, trembling, unusual tiredness, weakness, and mental
depression may result.